GLP-1s can deliver value to patients. But the fact that GLP-1s aren't cost-effective at their current net prices can limit ...

A rise in the use of non-FDA-approved diabetes and obesity medications has spurred health care professionals and medical ...

The once-daily pill combines Opko’s long-acting GLP-1/glucagon dual agonist peptide, dubbed OPK-88006, with Entera’s N-Tab ...

As obesity drug developers compete for the highest weight-loss efficacy, experts contend that overall health ...

G lucagon-like peptide-1 receptor agonists, aka GLP-1 agonists, such as semaglutide -- better known as Ozempic -- have ...

Tirzepatide — a drug that acts both as a GLP-1 agonist and a GIP agonist — is the active ingredient in an even more powerful ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

GLP-1 therapy is a groundbreaking approach in the treatment of obesity and metabolic health issues. GLP-1, or glucagon-like ...

In what it says is the biggest obesity deal to date, Zealand Pharma A/S has signed up Roche AG to a potential $5.3 billion ...

Roche and Zealand reason petrelintide could deliver weight loss comparable to glucagon-like peptide 1 (GLP-1) receptor agonists but without the side effects associated with GLP-1 drugs.

Profits and losses for petrelintide and the petrelintide/CT-388 combination will be shared on a 50:50 basis in the U.S. and Europe, while Zealand will be eligible to receive tiered double-digit ...

The deal gives the Swiss pharma access to an experimental amylin-targeting treatment it will test in combination with drugs ...